310 Mira Street, Stavropol, Russia, 355017
+7 8652 352524; +7 8652 353229.
+7 8652 352524.
The journal is included into The list of leading scientific periodicals.
[Clinical Pharmacology] [Pharmacology]
Maria Vladimirovna Lukina; Tatiana Evgenyevna Morozova; Tatyana Borisovna Andrushchishina; Maria Alexandrovna Chukina; Galina Vladislavovna Ramenskaya; Igor Evgenievich Shokhin;
For comparing the results of calculating the vancomycin clearance (Clvan) by various methods in patients after surgery with acute kidney injury (AKI). A prospective observational study was conducted in the University Clinical Hospital № 1. Objects were 61 patients with infectious complications after surgery. Patients were divided into 2 groups: 1st – patients with signs of acute kidney injury (AKI) (n=35, 66.6 %), 2nd – without AKI (n=26, 33.4 %). Clvan was calculated by different calculation methods: DeRyke, Pea, Moise –Broder, «ClinCalс», as well as actual concentrations obtained during pharmacokinetic study (PS). In AKI group Clvan values were 40.90±15.6 ml/min according to DeRyke, 41.79±10.3 ml/min, by Pea – 41.79±10.3 ml/min, by Moise – Broder – 58.49±16.6 ml/min, by ClinCalс – 48.53±22.12 ml/min, by TLM – 119.28±48.31 ml/min; in patients without AKI – 57.58±8.11; 52.45±5.19; 76.05±8.54; 63.29±19.28; 84.37±27.63 ml/min, respectively. Clvan values did not significantly differ being calculated by DeRyke and Pea methods (p=0.259). The remaining mean Clvan values differed significantly, Clvan values were significantly higher than the DeRyke values (p<0.001), Pea (p<0.001), Moise – Broder (p<0.001), ClinCalс (p<0.001). In AKI group, the relative error in the calculation accuracy Clvan according DeRyke, Pea, Moise – Broder, ClinCalс formulas was 60 %, 56 %, 43 %, 58 %, respectively; in the group without the AKI, the relative error in the calculation accuracy Clvan was 37 %, 49 %, 35 %, 47 %, respectively. The results of our study indicate that the use of different methods for calculating and predicting Clvan values based on calculated values of creatinine clearance is unjustified.
1. Matzke G. R., McGory R. W., Halstenson C. E., Keane W. F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob. Agents Chemother. 1984;25(4):433-437. https://doi.org/10.1128/AAC.25.4.433
2. Moise-Broder P. A., Forrest A., Birmingham M. C. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin.Pharmacokinet. 2004;43:925-942. https://doi.org/10.2165/00003088-200443130-00005
3. Bondareva I. B. Programmnoye obespecheniye dlya analiza dannykh FK/FD issledovaniy. Klinicheskaya farmakokinetika. – Clinical pharmacokinetics. 2005;2(3):9-13. (In Russ.).
4. Pea F., Furlanut M., Negri C. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother. 2009;53(5):1863-1867. https://doi.org/10.1128/AAC.01149-08
5. DeRyke C. A., Alexander D. P. Optimizing Vancomycin Dosing Through Pharmacodynamic Assessment Targeting Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hospital Pharmacy. 2009;44(9):751-765. https://doi.org/10.1310/hpj4409-751
6. Nakayama H., Echizen H., Tanaka M., Sato M., Orii T. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther. Drug. Monit. 2008;30(1):103- 107. https://doi.org/ 10.1097/FTD.0b013e318164f781
7. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical. Practice. 2012;120(4):179- 184. https://doi.org/10.1159/000339789
9. Hammett-Stabler C. A., Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin. Chem. 1998;44(5):1129-1240.
10. Rybak M., Lomaestro B., Rotschafer J. C. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2009;66:82-98.
11. Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2017. Available at:
12. Bauer L. A. Chapter 5. Vancomycin. In: Bauer L. A., ed. Applied Clinical Pharmacokinetics. 2nd ed. New York: McGraw-Hill, 2008. https://doi.org/10.1036/0071476288
13. Haeseker M., Croes S., Neef C., Bruggeman C., Stolk L., Verbon A. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels. Ther. Drug. Monit. 2016;38(1):120-126. https://doi.org/10.1097/FTD.0000000000000250
14. Lamb E. J., TomsonC. R., Roderick P. J. Estimatin g kidney function in adults using formulae. Ann. Clin. Biochem. 2005;42(5):321-345.
15. Levey A. S., Coresh J., Greene T., Marsh J., Stevens L. A. [et al.]. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007;53(4):766-772. https://doi.org/10.1373/clinchem.2006.077180
16. Lipman J., Udy A. A., Roberts J. A. Do we understandd the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth. Intensive Care. 2011;39(6):999-1000. https://doi.org/10.1177/0310057X1103900602
Keywords: vancomycin clearance, pharmacokinetic study, mathematical modeling, creatinine clearance